{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MSI-H&page=2", "query": { "condition": "MSI-H", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MSI-H&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T04:15:50.732Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05544929", "title": "A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Cutaneous Melanoma", "Carcinoma, Renal Cell", "Carcinoma, Ovarian Epithelial", "Nasopharyngeal Carcinoma", "Carcinoma, Thymic", "Anal Cancer", "Mesothelioma", "Esophagogastric Cancer", "High Microsatellite Instability Colorectal Carcinoma", "Squamous Cell Carcinoma of Head and Neck", "Triple Negative Breast Neoplasms" ], "interventions": [ { "name": "KFA115", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 126, "start_date": "2022-10-26", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-06-11T04:15:50.732Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05544929" }, { "nct_id": "NCT02060188", "title": "A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Microsatellite Unstable Colorectal Cancer", "Microsatellite Stable Colorectal Cancer", "Mismatch Repair Proficient Colorectal Cancer", "Mismatch Repair Deficient Colorectal Cancer" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "BMS-986016", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 385, "start_date": "2014-03-12", "completion_date": "2024-10-22", "has_results": true, "last_update_posted_date": "2025-11-06", "last_synced_at": "2026-06-11T04:15:50.732Z", "location_count": 14, "location_summary": "Gilbert, Arizona • Los Angeles, California • San Francisco, California + 10 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02060188" }, { "nct_id": "NCT03407976", "title": "Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancies", "Urothelial Carcinoma", "MSI-H or dMMR Solid Tumors", "Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma" ], "interventions": [ { "name": "Apatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2018-06-19", "completion_date": "2020-07-02", "has_results": false, "last_update_posted_date": "2020-07-15", "last_synced_at": "2026-06-11T04:15:50.732Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03407976" }, { "nct_id": "NCT07327489", "title": "Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "Immunotherapy", "Advanced Solid Tumors Cancer", "Bladder Cancer", "TNBC, Triple Negative Breast Cancer", "Colorectal Cancer", "DMMR Colorectal Cancer", "MSI-H Colorectal Cancer", "Endometrial Cancer", "Head and Neck Cancer", "Kidney Cancer", "Liver Cancer", "NSCLC (Non-small-cell Lung Cancer)", "Skin Cancer", "Melanoma (Skin Cancer)" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Elephas", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2000, "start_date": "2025-04-14", "completion_date": "2038-04", "has_results": false, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-06-11T04:15:50.732Z", "location_count": 8, "location_summary": "Fort Smith, Arkansas • Frederick, Maryland • Springfield, Missouri + 4 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Frederick", "state": "Maryland" }, { "city": "Springfield", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07327489" }, { "nct_id": "NCT02332668", "title": "A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Lymphoma", "Solid Tumor", "Classical Hodgkin Lymphoma", "Microsatellite-instability-high Solid Tumor" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Months to 17 Years" }, "enrollment_count": 370, "start_date": "2015-03-19", "completion_date": "2028-02-02", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-06-11T04:15:50.732Z", "location_count": 7, "location_summary": "Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02332668" }, { "nct_id": "NCT06205836", "title": "Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Fianlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2024-06-13", "completion_date": "2030-05", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-06-11T04:15:50.732Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06205836" }, { "nct_id": "NCT03589339", "title": "NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Radiotherapy", "Immunotherapy", "Microsatellite Instability-High Solid Malignant Tumour", "Metastasis From Malignant Tumor of Liver", "Squamous Cell Carcinoma of Head and Neck", "Metastasis From Malignant Tumor of Cervix", "Metastatic Renal Cell Carcinoma", "Metastasis From Malignant Melanoma of Skin (Disorder)", "Metastatic Triple-Negative Breast Carcinoma", "Metastatic NSCLC", "Metastasis From Malignant Tumor of Bladder (Disorder)" ], "interventions": [ { "name": "NBTXR3", "type": "DRUG" }, { "name": "SABR", "type": "RADIATION" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Nanobiotix", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2019-01-16", "completion_date": "2027-08-30", "has_results": false, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-06-11T04:15:50.732Z", "location_count": 13, "location_summary": "San Francisco, California • Tampa, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03589339" }, { "nct_id": "NCT06948448", "title": "A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "ONO-4578", "type": "DRUG" }, { "name": "Opdivo®", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ono Pharmaceutical Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 144, "start_date": "2025-11-18", "completion_date": "2028-10-01", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-06-11T04:15:50.732Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Los Angeles, California • Lone Tree, Colorado + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06948448" }, { "nct_id": "NCT04116320", "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Breast Cancer", "Merkel Cell Carcinoma", "Squamous Cell Cancer", "Non Small Cell Lung Cancer", "Cervical Cancer", "Urothelial Carcinoma", "Ovarian Cancer", "Hepatocellular Carcinoma", "Small-cell Lung Cancer", "Microsatellite Instability High", "Gastric Cancer", "Esophageal Cancer" ], "interventions": [ { "name": "Echopulse", "type": "DEVICE" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Standard of Care PD-1 Therapy", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Craig L Slingluff, Jr", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2019-11-21", "completion_date": "2023-08-15", "has_results": false, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-06-11T04:15:50.732Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04116320" }, { "nct_id": "NCT07270666", "title": "ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "ctDNA Testing", "type": "GENETIC" }, { "name": "Blood draw", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 30, "start_date": "2025-11-25", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-06-11T04:15:50.732Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07270666" } ] }